Dr. Mihaela Biscoveanu, MD
NPI: 1033159231
Total Payments
$58,973
2024 Payments
$1,891
Companies
17
Transactions
122
Medicare Patients
2,738
Medicare Billing
$300,537
Payment Breakdown by Category
Research$54,912 (93.1%)
Food & Beverage$2,058 (3.5%)
Travel$1,992 (3.4%)
Education$11.71 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $54,912 | 21 | 93.1% |
| Food and Beverage | $2,058 | 94 | 3.5% |
| Travel and Lodging | $1,992 | 6 | 3.4% |
| Education | $11.71 | 1 | 0.0% |
Payments by Type
Research
$54,912
21 transactions
General
$4,062
101 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $53,225 | 6 | $0 (2022) |
| ABBVIE INC. | $1,736 | 19 | $0 (2024) |
| Boehringer Ingelheim International GmbH | $1,323 | 6 | $0 (2019) |
| Novo Nordisk AS | $1,208 | 4 | $0 (2019) |
| Novo Nordisk Inc | $448.01 | 38 | $0 (2020) |
| Medtronic MiniMed, Inc. | $192.63 | 14 | $0 (2019) |
| Medtronic, Inc. | $168.85 | 7 | $0 (2024) |
| Radius Health, Inc. | $159.63 | 3 | $0 (2021) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $152.32 | 3 | $0 (2024) |
| Lilly USA, LLC | $114.91 | 8 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,891 | 27 | ABBVIE INC. ($1,701) |
| 2023 | $56.30 | 3 | Medtronic, Inc. ($37.08) |
| 2022 | $37,610 | 9 | Eli Lilly and Company ($37,479) |
| 2021 | $2,711 | 11 | Eli Lilly and Company ($2,446) |
| 2020 | $13,343 | 5 | Eli Lilly and Company ($13,300) |
| 2019 | $2,820 | 29 | Boehringer Ingelheim International GmbH ($1,323) |
| 2018 | $443.08 | 31 | Novo Nordisk Inc ($177.59) |
| 2017 | $98.58 | 7 | Novo Nordisk Inc ($86.37) |
All Payment Transactions
122 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Medtronic, Inc. | MINIMED 780G (Device) | Food and Beverage | In-kind items and services | $24.93 | General |
| Category: Durable Pump | ||||||
| 12/06/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $18.01 | General |
| Category: Endocrinology | ||||||
| 11/25/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $10.65 | General |
| 10/31/2024 | Mannkind Corporation | AFREZZA (Drug) | Food and Beverage | In-kind items and services | $21.60 | General |
| Category: DIABETES MEDICINE | ||||||
| 10/25/2024 | Medtronic, Inc. | MINIMED 780G (Device) | Food and Beverage | In-kind items and services | $17.09 | General |
| Category: Durable Pump | ||||||
| 10/07/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $24.11 | General |
| Category: Diabetes Care | ||||||
| 09/18/2024 | Tandem Diabetes Care, Inc. | t:slim X2 Insulin Pump with Control-IQ (Device) | Food and Beverage | In-kind items and services | $4.24 | General |
| Category: Endocrinology | ||||||
| 09/17/2024 | Tandem Diabetes Care, Inc. | t:slim X2 Insulin Pump with Control-IQ (Device) | Food and Beverage | In-kind items and services | $13.62 | General |
| Category: Endocrinology | ||||||
| 07/27/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $3.29 | General |
| 05/23/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $26.92 | General |
| Category: Endocrinology | ||||||
| 05/16/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $20.67 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 04/12/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $646.73 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/12/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $69.00 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/12/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $50.54 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/12/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $37.50 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/12/2024 | ABBVIE INC. | — | — | In-kind items and services | $26.33 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism | ||||||
| 04/12/2024 | ABBVIE INC. | — | — | In-kind items and services | $25.69 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism | ||||||
| 04/11/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $226.86 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/11/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $125.05 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/11/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $70.25 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/11/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $50.54 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/11/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $37.50 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/11/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $25.00 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/10/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $226.86 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/10/2024 | ABBVIE INC. | — | — | In-kind items and services | $55.91 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN DEGLUDEC IN INSULIN NAIVE ADULTS WITH TYPE 2 DIABETES | Eli Lilly and Company | $37,448 | 2 |
| THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | Eli Lilly and Company | $15,777 | 4 |
| A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism | ABBVIE INC. | $1,687 | 15 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 658 | 980 | $170,405 | $63,751 |
| 2022 | 8 | 710 | 1,122 | $217,145 | $73,795 |
| 2021 | 10 | 638 | 1,208 | $260,845 | $80,979 |
| 2020 | 12 | 732 | 1,245 | $282,215 | $82,012 |
Total Patients
2,738
Total Services
4,555
Medicare Billing
$300,537
Procedure Codes
40
All Medicare Procedures & Services
40 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 206 | 268 | $73,775 | $24,329 | 33.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 89 | 255 | $33,150 | $16,245 | 49.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 66 | 68 | $16,660 | $7,265 | 43.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 40 | 40 | $14,000 | $5,030 | 35.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 36 | 38 | $13,300 | $4,510 | 33.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 51 | 55 | $10,450 | $3,272 | 31.3% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 32 | 50 | $3,750 | $1,966 | 52.4% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2023 | 115 | 174 | $2,610 | $555.33 | 21.3% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 12 | 14 | $1,540 | $366.99 | 23.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 11 | 18 | $1,170 | $211.32 | 18.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 192 | 258 | $74,325 | $25,279 | 34.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 131 | 391 | $63,580 | $22,561 | 35.5% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 86 | 89 | $27,475 | $9,709 | 35.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 32 | 36 | $13,600 | $5,275 | 38.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 61 | 70 | $13,740 | $4,317 | 31.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 35 | 35 | $14,450 | $4,082 | 28.3% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 53 | 63 | $6,275 | $1,992 | 31.7% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2022 | 120 | 180 | $3,700 | $580.02 | 15.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 185 | 308 | $92,400 | $31,581 | 34.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 128 | 461 | $94,505 | $28,119 | 29.8% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 77 | 81 | $30,780 | $9,045 | 29.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 50 | 62 | $12,400 | $3,953 | 31.9% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 25 | 25 | $11,250 | $3,327 | 29.6% |
| 76536 | Ultrasound of head and neck | Office | 2021 | 19 | 19 | $7,220 | $1,705 | 23.6% |
| 10005 | Fine needle aspiration of first lesion using ultrasound guidance | Office | 2021 | 12 | 12 | $2,400 | $1,423 | 59.3% |
About Dr. Mihaela Biscoveanu, MD
Dr. Mihaela Biscoveanu, MD is a Endocrinology, Diabetes & Metabolism healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1033159231.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mihaela Biscoveanu, MD has received a total of $58,973 in payments from pharmaceutical and medical device companies, with $1,891 received in 2024. These payments were reported across 122 transactions from 17 companies. The most common payment nature is "" ($54,912).
As a Medicare-enrolled provider, Biscoveanu has provided services to 2,738 Medicare beneficiaries, totaling 4,555 services with total Medicare billing of $300,537. Data is available for 4 years (2020–2023), covering 40 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Philadelphia, PA
- Active Since 06/07/2006
- Last Updated 10/03/2016
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1033159231
Products in Payments
- ARMOUR THYROID (Drug) $1,566
- JARDIANCE (Drug) $1,492
- Ozempic (Drug) $189.28
- Minimed 670G System (Device) $174.62
- Tymlos (Biological) $159.63
- Victoza (Drug) $95.89
- MINIMED 780G (Device) $79.10
- MINIMED 770G (Device) $71.68
- TRULICITY (Drug) $68.02
- Levemir (Drug) $46.31
- Dexcom G6 Transmitter (Medical Supply) $44.93
- XARELTO (Drug) $39.89
- INVOKANA (Drug) $34.62
- t:slim X2 Insulin Pump with Control-IQ (Device) $33.31
- FREESTYLE LIBRE 3 (Device) $24.11
- AFREZZA (Drug) $21.60
- BAQSIMI (Drug) $19.19
- Thyquidity (Drug) $18.97
- INPEN SMART INSULIN DELIVERY SYSTEM (Device) $18.07
- Minimed 630G (Device) $18.01
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Philadelphia
Dr. Serge Jabbour, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $1.7M
Endocrinology, Diabetes & Metabolism $1.7M
Jane Mayrin, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $928,176
Endocrinology, Diabetes & Metabolism $928,176
Mitchell Lazar, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $432,095
Endocrinology, Diabetes & Metabolism $432,095
Jeffrey Freeman, D.o, D.O
Endocrinology, Diabetes & Metabolism — Payments: $403,058
Endocrinology, Diabetes & Metabolism $403,058
Dr. Monika Shirodkar, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $59,532
Endocrinology, Diabetes & Metabolism $59,532
Michael Rickels, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $41,645
Endocrinology, Diabetes & Metabolism $41,645